iPSCs and NSCs have significantly improved the study of genetic alterations in glioblastoma, highlighting the roles of PTEN deficiency and CHI3L1 expression in tumor development and aiding in therapeutic strategy formulation. This evidence concerns the gene CHI3L1 and neoplasm.